Difficult-to-treat hypertensive populations: Focus on African-Americans and people with type 2 diabetes

Journal of Hypertension, Supplement

Volumn 17, Issue 1, 1999, Pages

  Flack, John M ^a   Hamaty, Marwan ^a  

^a WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

African American; Angiotensin converting enzyme inhibitors; Diabetes mellitus; Monotherapy

Indexed keywords

ACETYLSALICYLIC ACID; ADRENERGIC RECEPTOR BLOCKING AGENT; ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; AMLODIPINE; ANGIOTENSIN; ANGIOTENSIN 1 RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; ATENOLOL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BRADYKININ; CALCIUM ANTAGONIST; CAPTOPRIL; CHLORTALIDONE; DIHYDROPYRIDINE DERIVATIVE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; DOXAZOSIN; FELODIPINE; FOSINOPRIL; KININ; LISINOPRIL; LOSARTAN POTASSIUM; METOLAZONE; NISOLDIPINE; NITRIC OXIDE; QUINAPRIL; RENIN; SODIUM CHLORIDE; THIAZIDE DIURETIC AGENT; VERAPAMIL;

AUTONOMIC NEUROPATHY; BLOOD FLOW; BLOOD PRESSURE; BLOOD PRESSURE REGULATION; CARDIOVASCULAR RISK; CLINICAL TRIAL; CONFERENCE PAPER; CONGESTIVE HEART FAILURE; DRUG EFFICACY; DYSLIPIDEMIA; ETHNIC GROUP; GINGIVA HYPERPLASIA; HEART DISEASE; HIGH RISK POPULATION; HUMAN; HYPERKALEMIA; HYPERTENSION; HYPOGLYCEMIA; HYPOKALEMIA; HYPOTENSION; KIDNEY DISEASE; KIDNEY FAILURE; META ANALYSIS; NATRIURESIS; NON INSULIN DEPENDENT DIABETES MELLITUS; PHENOTYPE; PREVALENCE; PRIORITY JOURNAL; PROTEINURIA; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; STROKE; TACHYCARDIA; TARGET ORGAN; TISSUE INJURY; UNITED STATES;

AFRICAN CONTINENTAL ANCESTRY GROUP; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; DIABETES MELLITUS, TYPE 2; DRUG THERAPY, COMBINATION; HUMANS; HYPERTENSION; PREVALENCE; RISK FACTORS; UNITED STATES;

EID: 0032973364     PISSN: 09521178     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (45)

1. The Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure and the National High Blood Pressure Education Program Coordinating Committee. The Sixth Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Arch Intern Med 1997; 157:2413-2446.
2. Stamler J, Vaccaro O, Neaton JD, Wentworth D. Diabetes, other risk factors, and 12-yr cardiovascular mortality for men screened in the Multiple Risk Factor Intervention Trial. Diabetes Care 1993; 16:434-444.
3. Assmann G, Schulte H. The Prospective Cardiovascular Munster (PROCAM) study: prevalence of hyperlipidemia in persons with hypertension and/or diabetes mellitus and the relationship to coronary heart disease. Am Heart J 1988; 116:1713-1724.
4. US Department of Health and Human Services. Chronic Disease in Minority Populations. Atlanta, GA: US Department of Health and Human Services, Public Health Service, Centers for Disease Control and Prevention, National Center for Chronic Disease Prevention and Health Promotion; 1992.
5. Cooper R, Rotimi C. Hypertension in blacks. Am J Hypertens 1997; 7:804-812.
6. US Department of Health and Human Services. Health United States, 1994. Hyattsville, MD: US Department of Health and Human Services, Public Health Service; 1995.
7. Saunders E. Hypertension in minorities: blacks. Am J Hypertens 1995; 8:115S-119S.
8. Burt VL, Whelton P, Rocella EJ, Brown C, Cutler JA, Higgins M, et al. Prevalence of hypertension in the US adult population: results from the third National Health and Nutrition Examination Survey, 1988-1991. Hypertension 1995; 25:305-313.
9. Hall WD, Ferrario CM, Moore MA, Hall JE, Flack JM, Cooper W, et al. Hypertension related morbidity and mortality in the southeastern United States. Am J Med Sci 1997; 313:195-206.
10. Flack JM, Yunis C, Preisser J, Staffileno BA, Mensah G, Saunders E. The accupril titration interval management evaluation (ATIME) trial. Am J Hypertens 1998; 11:103A.
11. Flack JM. Therapy of hypertension. In: Greenberg A, Cheung AK (editors): Primer on kidney diseases. 2nd edition. San Diego, CA: Academic Press; 1998. pp. 506-516.
12. Hypertension Detection and Follow-up Program Cooperative Group. Five-year findings of the Hypertension Detection and Follow-up Program: mortality by race, sex and blood pressure level. A further analysis. J Community Health 1984; 9:314-327.
13. Kaplan NM. Ethnic aspects of hypertension. Lancet 1994; 344:450-452
14. Neaton JD, Kuller LH, Wentworth D, Borhani NO. Total and cardiovascular mortality in relation to cigarette smoking, serum cholesterol concentration, diastolic blood pressure among black and white males followed up for five years. Am Heart J 1984; 108:759-769.
15. Prineas RJ, Fillum RF. US epidemiology of hypertension in blacks. In: Hall WD, Saunders E, Shulman NB (editors): Hypertension in Blacks: Epidemiology, Pathophysiology and Treatment. Chicago, IL: Year Book Medical Publishers Inc.; 1985. pp. 17-37.
16. Flack JM, Wiist WH. Epidemiology of hypertension and hypertensive target-organ damage in the United States. J Assoc Acad Minority Phys 1991; 2:143-150.
17. Ganguli MC, Grimm RH Jr, Svendsen KH, Flack JM, Grandits GA, Elmer PJ. Higher education and income are related to a better Na:K ratio in blacks: baseline results of the Treatment of Mild Hypertension Study (TOMHS) data. Am J Hypertens 1997; 10:979-984.
18. He FJ, Markandu ND, Sagnella GA, MacGregor GA. Importance of the renin system in determining blood pressure fall with salt restriction in black and white hypertensives. Hypertension 1998; 32:820-824.
19. Weir MR, Hall PS, Behrens MT, Flack JM. Salt and blood pressure responses to calcium antagonism in hypertensive patients. Hypertension 1997; 30:422-427.
20. Weir MR, Chrysant SG, McCarron DA, Canossa-Terris M, Cohen JD, Gunter PA, et al. Influence of race and dietary salt on the antihypertensive efficacy of an angiotensin-converting enzyme inhibitor or a calcium channel antagonist in salt-sensitive hypertensives. Hypertension 1998; 31:1088-1096.
21. Harshfield GA, Hwang C, Grim CE. Circadian variation of blood pressure in blacks: influence of age, gender, and activity. J Hum Hypertens 1990; 4:43-47.
22. Harshfield GA, Pulliam DA, Somes GW, Alpert BS. Ambulatory blood pressure patterns in youth. Am J Hypertens 1993; 6:968-973.
23. Stein CM, Lang CC, Nelson R, Brown M, Wood AJ. Vasodilation in black Americans: attenuated nitric oxide-mediated responses. Clin Pharmacol Ther 1997; 62:436-443.
24. Flack JM, Hamaty M, Staffileno B. Renin-angiotensin-aldosterone-kinin system influences on diabetic vascular disease and cardiomyopathy. Miner Electrolyte Metab 1998; 24:412-422.
25. Expert Committee on the Diagnosis and Classification of diabetes mellitus. Report of the Expert Committee on the Diagnosis and Classification of diabetes mellitus. Diabetes Care 1998; 21 (suppl I):S50-S53.
26. The Hypertension in Diabetes Study Group. Hypertension in Diabetes Study (HDS): I. Prevalance of hypertension in newly presenting type 2 diabetic patients and the association with risk factors for cardiovascular and diabetic complications. J Hypertens 1993; 11:309-317.
27. Krolewski AS, Canessa M, Warram JH. Predisposition to hypertension and susceptibility to renal disease to insulin-dependent diabetes mellitus. N Engl J Med 1988; 318: 140-145.
28. Brancati FL, Whelton PK, Randall BL, Neaton JD, Stamler J, Klag MJ. Risk of end-stage renal disease in diabetes mellitus: A prospective cohort study of men screened for MRFIT. Multiple Risk Factor Intervention Trial. JAMA 1997; 278:2069-2074.
29. Dinneen SF, Gerstein HC. The association of microalbuminuria and mortality in non-insulin-dependent diabetes mellitus. A systematic overview of the literature. Arch Intern Med 1997; 157:1413-1418.
30. Jensen JS, Feldt-Rasmussen B, Borch-Johnsen K, Clausen P, Appleyard M, Jensen G. Microalbuminuria and its relation to cardiovascular disease and risk factors. A population-based study of 1254 hypertensive individuals. J Hum Hypertens 1997; 11:727-732.
31. Curb JD, Pressel SL, Cutler JA, Savage PJ, Applegate WB, Black H, et al. Effect of diuretic-based antihypertensive treatment on cardiovascular disease risk in older diabetic patients with isolated systolic hypertension. JAMA 1996; 276:1886-1892.
32. UK Prospective Diabetes Study Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. BMJ 1998; 317:703-713.
33. Hansson L, Zanchetti A, Carruthers SG, Dahlǒf B, Elmfeldt D, Julius S, et al. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. Lancet 1998; 351:1755-1762.
34. Hasslacher C, Bostedt-Kiesel A, Kempe HP, Wahl P. Effect of metabolic factors and blood pressure on kidney function in proteinuric type 2 (non-insulin-dependent) diabetic patients. Diabetologia 1993; 36:1051-1056.
35. Schmitz A, Vaeth M, Mogensen CE. Systolic blood pressure relates to the rate of progression of albuminuria in NIDDM. Diabetologia 1994; 37:1251-1258.
36. Estacio RO, Jeffers BW, Hiatt WR, Biggerstaff SL, Gifford N, Schrier RW. The effect of nisoldipine as compared with enalapril on cardiovascular outcomes in patients with non-insulin-dependent diabetes and hypertension. N Engl J Med 1998; 338:645-654.
37. Tatti P, Pahor M, Byington RP, Di Mauro P, Guarisco R, Strollo G, et al. Outcome results of the Fosinopril versus Amlodipine Cardiovascular Events Randomized Trial (FACET) in patients with hypertension and NIDDM. Diabetes Care 1998; 21:597-603.
38. UK Prospective Diabetes Study Group. Efficacy of atenolol and captopril in reducing risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 39. BMJ 1998; 317:713-720.
39. Davis BR, Cutler JA, Gordon DJ, Furberg CD, Wright JT Jr, Cushman WC, et al. Rationale and design for the Antihypertensive and Lipid Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). ALLHAT Research Group. Am J Hypertens 1996; 9:342-360.
40. Chaturvedi N, Sjolie AK, Stephenson JM, Abrahamian H, Keipes M, Castellarin A, Rogulja-Pepeonik Z, Fuller JH, and the EUCLID Study Group. Effect of lisinopril on progression of retinopathy in normotensive people with type 1 diabetes. Lancet 1998; 351:28-31.
41. The EUCLID Study Group. Randomised placebo controlled trial of lisinopril in normotensive patients with insulin dependent diabetes and normoalbuminuria or microalbuminuria. Lancet 1997; 349:1787-1792.
42. Uribarri J, Oh MS, Carroll HJ. Hyperkalemia in diabetes mellitus. J Diabetes Complications 1990; 4:3-7.
43. Klein R. Hyperglycemia and microvascular and macrovascular disease in diabetes. Diabetes Care 1995; 18:258-268.
44. Ohkubo Y, Kishikawa H, Araki E, Miyata T, Isami S, Motoyoshi S, et al. Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus: a randomized prospective 6-year study. Diabetes Res Clin Pract 1995; 28:103-117.
45. Tanaka Y, Atsumi Y, Matsuoka K, Onuma T, Tohjima T, Kawamori R. Role of glycemic control and blood pressure in the development and progression of nephropathy in elderly Japanese NIDDM patients. Diabetes Care 1998; 21:116-120.